drugset
Drugs / BNT162
last change Nov 2022 re-read 3 minutes ago

BNT162

Messenger RNA (mRNA)

Investigated by
Novartis Pharmaceuticals

Trials 1

today NCT04792567 · Ph 4
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04792567 Apr → Sep 2021 secondary progressive multiple sclerosis Novartis Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2020-09-15 BioNTech SE BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162 biontech.com ↗
2020-08-28 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR fosunpharma.com ↗
2020-08-27 BioNTech SE BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR biontech.com ↗
2020-08-05 Pfizer Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate pfizer.com ↗
2020-08-05 BioNTech SE Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate biontech.com ↗
2020-07-31 Pfizer Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate pfizer.com ↗
2020-07-31 BioNTech SE Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate biontech.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BNT162 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04792567 ↗
Modality Messenger RNA (mRNA) “SARS-CoV-2 mRNA vaccines” PMID 36381503 ↗ Nov 2022